COYA - Company ID 0001835022
Coya Therapeutics, Inc. trades as COYA. In its fiscal 2025 annual report the company posted revenue of $7.95M, up 123.6% from the prior year and net income of -$21.23M. This page tracks Coya Therapeutics, Inc. through 222 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin compressed from -133.1% to -267.1% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Annual report to shareholders | ARS | 2026-05-13 |
| Proxy materials | DEFA14A | 2026-05-13 |
| Proxy statement | DEF 14A | 2026-05-13 |
| Major company event | 8-K | 2026-05-12 |
| Prospectus supplement | 424B5 | 2026-05-12 |
| Quarterly report | 10-Q | 2026-05-12 |
| Major company event | 8-K | 2026-05-12 |
| Insider trade | 4 | 2026-04-09 |
The largest companies sharing Coya Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Coya Therapeutics, Inc. reported revenue of $7.95M for fiscal year 2025, an increase of 123.6% year over year.
In its latest fiscal year Coya Therapeutics, Inc. reported a net loss of $21.23M.